Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment Abstract #2753

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)
Aim(s): To evaluate risk of PRRT-associated bowel obstruction and assess treatment strategies
Materials and methods: Records of all patients treated with 177-Lutetium-dotatate at the Moffitt Cancer Center between 4/2018 and 10/2019 were evaluated. The number of patients who developed bowel obstruction within 3 months of a treatment cycle was divided by the total number of patients with preexisting peritoneal or mesenteric disease. Management strategies and outcomes were evaluated
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Jonathan Strosberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christopher Wee
Authors: Wee C, Dundar A, Packard A, Kendi A T, ...
#1577 Peritoneal Carcinomatosis in Digestive Neuroendocrine Neoplasms: Complications and Response to Therapy
Introduction: Peritoneal carcinomatosis (PC) is present in 10-30% of digestive neuroendocrine neoplasms (DNENs), affecting prognosis and quality of life with recurrent abdominal pain and bowel obstruction
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, PhD Elettra Merola
#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#423 Case Report : A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids
Introduction: Retroperitoneal fibrosis is a rare inflammatory disease. Neuroendocrine tumors are a heterogenous group that arise from enterochromaffin cells, most commonly in the gastrointestinal tract. Their capacity to secrete hormones, five HT, tachykinins etc, are responsible for symptoms known as carcinoid syndrome. However NETS, particularly arising from the midgut, can cause fibrosis. This can result in bowel obstruction, but also cause fibrosis in the retroperitoneum, lungs and cardiac valvular fibrosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
Authors: Mandair D, Mangat K, Malaki M, Shah T, ...